These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 37971614

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.
    Little KM, Flomen L, Hanif H, Anderson SM, Thurman AR, Clark MR, Doncel GF.
    AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection.
    Vickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F.
    BMC Infect Dis; 2020 Sep 25; 20(1):704. PubMed ID: 32977745
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, Rousseau E, Travill D, Morton JF, Mogaka F, O'Malley G, Barnabee G, van der Straten A, Donnell D, Parikh UM, Kudrick L, Anderson PL, Haberer JE, Wu L, Heffron R, Johnson R, Morrison S, Baeten JM, POWER Study Team.
    J Int AIDS Soc; 2022 Jul 25; 25(7):e25962. PubMed ID: 35822945
    [Abstract] [Full Text] [Related]

  • 9. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
    Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, Pathak S, Bekker LG, Swaminathan S, Stanton J, Farrior J, Sista N.
    J Int AIDS Soc; 2019 Oct 25; 22(10):e25408. PubMed ID: 31651098
    [Abstract] [Full Text] [Related]

  • 10. A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa.
    Dietrich JJ, Atujuna M, Tshabalala G, Hornschuh S, Mulaudzi M, Koh M, Ahmed N, Muhumuza R, Ssemata AS, Otwombe K, Bekker LG, Seeley J, Martinson NA, Terris-Prestholt F, Fox J.
    BMC Health Serv Res; 2021 Jan 06; 21(1):17. PubMed ID: 33407395
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J, Donnell D, Hosek S, Anderson PL, Chirenje ZM, Mgodi N, Bekker LG, Marzinke MA, Delany-Moretlwe S, Celum C.
    Lancet HIV; 2022 Oct 06; 9(10):e680-e689. PubMed ID: 36087612
    [Abstract] [Full Text] [Related]

  • 13. Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment.
    Chen Y, Saldarriaga EM, Montano MA, Ngure K, Thuo N, Kiptinness C, Rafferty M, Terris-Prestholt F, Stergachis A, Mugambi ML, Ortblad KF, Sharma M.
    BMJ Open; 2023 Apr 03; 13(4):e069195. PubMed ID: 37012008
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
    Mack N, Evens EM, Tolley EE, Brelsford K, Mackenzie C, Milford C, Smit JA, Kimani J.
    J Int AIDS Soc; 2014 Apr 03; 17(3 Suppl 2):19157. PubMed ID: 25224616
    [Abstract] [Full Text] [Related]

  • 18. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA.
    J Int AIDS Soc; 2019 Dec 03; 22(12):e25427. PubMed ID: 31855323
    [Abstract] [Full Text] [Related]

  • 19. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY, Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Terris-Prestholt F.
    BMC Public Health; 2019 Jul 24; 19(1):996. PubMed ID: 31340785
    [Abstract] [Full Text] [Related]

  • 20. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A, Sharma M, Akullian AN, Peebles K, Sarkar S, Braithwaite RS, Mudimu E.
    J Int AIDS Soc; 2020 Jun 24; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.